Tag Archives: CSSRS

Better Safe than Sorry: Assessing Suicide Risk in Clinical Trials

With the FDA striving to avoid post-market reactions to drugs with worrisome side-effect profiles, preventive measures that screen for obvious risks such as suicidal behavior and abuse potential are making their way into the lexicon of regulators and drug developers alike, in tandem with its mandate that stresses safety first and efficacy a close second. […]
Posted in compliance, FDA, R&D, Regulatory, Safety, Strategy | Also tagged , , , , , , , , | 2 Comments
  • Categories

  • Meta